阿维巴坦恢复嗜麦芽寡养单胞菌临床分离株对氨曲南的敏感性。
Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
机构信息
Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
出版信息
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00777-17. Print 2017 Oct.
Abstract
is an emerging opportunistic pathogen, classified by the World Health Organization as one of the leading multidrug-resistant organisms in hospital settings. The need to discover novel compounds and/or combination therapies for is urgent. We demonstrate the efficacy of aztreonam-avibactam (ATM-AVI) against and kinetically characterize the inhibition of the L2 β-lactamase by avibactam. ATM-AVI overcomes aztreonam resistance in selected clinical strains of , addressing an unmet medical need.
摘要
是一种新兴的机会性病原体，世界卫生组织将其列为医院环境中主要的多药耐药病原体之一。迫切需要发现针对 的新型化合物和/或联合疗法。我们证明了阿兹台伦-阿维巴坦（ATM-AVI）对 的疗效，并对阿维巴坦抑制 L2 β-内酰胺酶的动力学进行了特征描述。ATM-AVI 克服了选定的临床分离株中的阿唑仑耐药性，满足了未满足的医疗需求。
相似文献
1
Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.阿维巴坦恢复嗜麦芽寡养单胞菌临床分离株对氨曲南的敏感性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00777-17. Print 2017 Oct.
2
Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.阿维巴坦增强了头孢他啶和氨曲南对体外嗜麦芽窄食单胞菌临床分离株的活性。
BMC Microbiol. 2021 Feb 22;21(1):60. doi: 10.1186/s12866-021-02108-2.
3
Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.美国嗜麦芽寡养单胞菌分离株的种群结构、分子流行病学和β-内酰胺酶多样性。
mBio. 2019 Jul 2;10(4):e00405-19. doi: 10.1128/mBio.00405-19.
4
Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.头孢他啶阿维巴坦、克拉维酸、雷利巴坦和沃博巴坦对多重耐药嗜麦芽窄食单胞菌的活性。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.00297-20.
5
Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli.多中心评价阿兹提罗单抗与阿维巴坦、雷利巴坦和沃巴坦联合用于治疗产金属β-内酰胺酶的碳青霉烯类耐药革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0069324. doi: 10.1128/aac.00693-24. Epub 2024 Aug 19.
6
Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates.非经典β-内酰胺酶抑制剂对广泛耐药嗜麦芽窄食单胞菌临床分离株疗效的结构/机制见解
Mol Microbiol. 2017 Nov;106(3):492-504. doi: 10.1111/mmi.13831. Epub 2017 Sep 21.
7
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.替加环素-阿维巴坦和对照药物对来自全球医疗中心的大量当代嗜麦芽寡养单胞菌分离株的抗菌活性研究。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01433-20.
8
Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.雷巴他定对 A 类β-内酰胺酶抑制的分子基础。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00564-19. Print 2019 Oct.
9
Looking for treatment: in vitro activity of ceftazidime/avibactam alone and in combination with aztreonam.寻找治疗方法：头孢他啶/阿维巴坦单独及联合氨曲南的体外活性。
J Chemother. 2023 Nov;35(7):610-613. doi: 10.1080/1120009X.2023.2247199. Epub 2023 Aug 24.
10
In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.β-内酰胺类抗生素联合阿维巴坦对来自囊性纤维化患者的多重耐药铜绿假单胞菌、嗜麦芽寡养单胞菌和木糖氧化无色杆菌分离株的体外活性研究。
J Med Microbiol. 2018 Sep;67(9):1217-1220. doi: 10.1099/jmm.0.000801. Epub 2018 Jul 17.
引用本文的文献
1
Management of infection and ocular complications in pediatric SJS/TEN-like acute graft-versus-host disease: a clinical case study and literature review.儿童类中毒性表皮坏死松解症/史蒂文斯-约翰逊综合征急性移植物抗宿主病感染及眼部并发症的管理：一项临床病例研究及文献综述
Front Immunol. 2025 Jun 16;16:1588297. doi: 10.3389/fimmu.2025.1588297. eCollection 2025.
2
Aztreonam plus ceftazidime-avibactam for post-neurosurgical meningitis due to .氨曲南加头孢他啶-阿维巴坦用于治疗由……引起的神经外科术后脑膜炎。 （原文此处病因未完整给出）
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0017225. doi: 10.1128/aac.00172-25. Epub 2025 Jun 2.
3
Ceftazidime retains efficacy against strains of for which traditional testing predicts resistance.头孢他啶对传统检测预测为耐药的菌株仍保持疗效。
mSphere. 2025 Jun 25;10(6):e0084024. doi: 10.1128/msphere.00840-24. Epub 2025 May 22.
4
Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli.多中心评价阿兹提罗单抗与阿维巴坦、雷利巴坦和沃巴坦联合用于治疗产金属β-内酰胺酶的碳青霉烯类耐药革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0069324. doi: 10.1128/aac.00693-24. Epub 2024 Aug 19.
5
Deciphering the Coevolutionary Dynamics of L2 β-Lactamases via Deep Learning.通过深度学习破译 L2 型β-内酰胺酶的协同进化动态。
J Chem Inf Model. 2024 May 13;64(9):3706-3717. doi: 10.1021/acs.jcim.4c00189. Epub 2024 Apr 30.
6
Novel case of combination antibiotic therapy for treatment of a complicated polymicrobial urinary tract infection with one organism harboring a metallo-β-lactamase (MBL) in a pregnant patient.一名孕妇患有复杂的多种微生物尿路感染，其中一种病原体携带金属β-内酰胺酶（MBL），采用联合抗生素治疗的新病例。
IDCases. 2024 Apr 15;36:e01946. doi: 10.1016/j.idcr.2024.e01946. eCollection 2024.
7
Characterization of a Novel Pathogen in Immunocompromised Patients: -Exploring the Scope of Resistance to Contemporary Antimicrobial Agents and β-lactamase Inhibitors.免疫功能低下患者中一种新型病原体的特征：探索对当代抗菌药物和β-内酰胺酶抑制剂的耐药范围
Open Forum Infect Dis. 2023 Jan 31;10(2):ofad014. doi: 10.1093/ofid/ofad014. eCollection 2023 Feb.
8
Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study.最后手段β-内酰胺类抗生素治疗新型德里金属β-内酰胺酶产生肠杆菌科和其他革兰氏阴性菌的难治性耐药：一项真实世界研究。
Front Cell Infect Microbiol. 2022 Dec 5;12:1048633. doi: 10.3389/fcimb.2022.1048633. eCollection 2022.
9
Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion.耐碳青霉烯类革兰阴性菌感染的流行病学、耐药机制及治疗方案：专家小组意见
Antibiotics (Basel). 2022 Sep 17;11(9):1263. doi: 10.3390/antibiotics11091263.
10
Clinical challenges treating infections: an update.感染治疗中的临床挑战：最新进展
JAC Antimicrob Resist. 2022 May 5;4(3):dlac040. doi: 10.1093/jacamr/dlac040. eCollection 2022 Jun.
本文引用的文献
1
Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus.持续性金黄色葡萄球菌感染的囊性纤维化患者肺功能较差的相关因素
PLoS One. 2016 Nov 18;11(11):e0166220. doi: 10.1371/journal.pone.0166220. eCollection 2016.
2
Phenotypic and Genotypic Diversity during a 10-year Colonization in the Lungs of a Cystic Fibrosis Patient.囊性纤维化患者肺部10年定植过程中的表型和基因型多样性
Front Microbiol. 2016 Sep 30;7:1551. doi: 10.3389/fmicb.2016.01551. eCollection 2016.
3
Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient.肾移植患者中由产金属β-内酰胺酶的嗜麦芽窄食单胞菌引起的血流感染的成功治疗
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5130-4. doi: 10.1128/AAC.00264-16. Print 2016 Sep.
4
Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.嗜麦芽窄食单胞菌引起的感染最新情况，特别关注耐药机制和治疗选择。
Front Microbiol. 2015 Sep 2;6:893. doi: 10.3389/fmicb.2015.00893. eCollection 2015.
5
Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study.阿维巴坦对肺炎克雷伯菌β-内酰胺酶（SHV-1和KPC-2）的抑制作用：一项结构研究。
PLoS One. 2015 Sep 4;10(9):e0136813. doi: 10.1371/journal.pone.0136813. eCollection 2015.
6
Interplay among membrane-bound lytic transglycosylase D1, the CreBC two-component regulatory system, the AmpNG-AmpDI-NagZ-AmpR regulatory circuit, and L1/L2 β-lactamase expression in Stenotrophomonas maltophilia.嗜麦芽窄食单胞菌中膜结合溶菌转糖基酶D1、CreBC双组分调节系统、AmpNG-AmpDI-NagZ-AmpR调节回路与L1/L2β-内酰胺酶表达之间的相互作用。
Antimicrob Agents Chemother. 2015 Nov;59(11):6866-72. doi: 10.1128/AAC.05179-14. Epub 2015 Aug 17.
7
Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.囊性纤维化患者呼吸道细菌学的流行病学变化
Chest. 2016 Feb;149(2):390-400. doi: 10.1378/chest.15-0676. Epub 2016 Jan 12.
8
In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.氨曲南-阿维巴坦对2012年和2013年全球革兰氏阴性病原菌菌株集的体外活性
Antimicrob Agents Chemother. 2015 Jul;59(7):4239-48. doi: 10.1128/AAC.00206-15. Epub 2015 May 11.
9
The β-lactamase gene regulator AmpR is a tetramer that recognizes and binds the D-Ala-D-Ala motif of its repressor UDP-N-acetylmuramic acid (MurNAc)-pentapeptide.β-内酰胺酶基因调节蛋白AmpR是一种四聚体，它能识别并结合其阻遏物UDP-N-乙酰胞壁酸（MurNAc）-五肽的D-Ala-D-Ala基序。
J Biol Chem. 2015 Jan 30;290(5):2630-43. doi: 10.1074/jbc.M114.618199. Epub 2014 Dec 5.
10
Antibiotic-resistant gram-negative bacterial infections in patients with cancer.癌症患者的耐抗生素革兰氏阴性菌感染
Clin Infect Dis. 2014 Nov 15;59 Suppl 5(Suppl 5):S335-9. doi: 10.1093/cid/ciu612.
Zotero 插件